HRT Pellets vs. Patches, Creams & Injections: What the Evidence Shows

Hormone replacement therapy has never been a single treatment. It is a family of delivery methods, each moving the same molecules through the body by different routes, at different speeds, with different risk profiles. Among these, HRT pellets have attracted disproportionate commercial enthusiasm, particularly in the direct-to-consumer wellness space, where they are marketed as the "set it and forget it" solution to hormonal decline. A small pellet, roughly the size of a grain of rice, is implanted under the skin of the hip or buttock every three to six months and releases hormones continuously until it dissolves. The appeal is real. The complications, however, are also real, and the clinical literature paints a considerably more nuanced picture than the marketing suggests.

Understanding HRT pellets requires understanding the broader landscape of hormone delivery: what estradiol, testosterone, and progesterone actually do in the body, why route of administration matters at the molecular level, and what decades of comparative data say about efficacy, safety, and dose controllability across all available options. This article examines all of that, because the choice of delivery method is not merely a matter of convenience. It carries implications for cardiovascular health, cancer risk, bone density, and the long-term trajectory of a person's healthspan.

What HRT Pellets Are and How They Work

HRT pellets are small, cylindrical implants compounded from crystallized hormones, most commonly testosterone, estradiol, or both, bound together with stearic acid or a similar excipient. They are inserted through a minor outpatient procedure: a physician or trained provider makes a small incision in the subcutaneous fat of the upper buttock or hip, places the pellet into the pocket using a trocar, and closes the wound with adhesive strips or a suture. No stitches are typically required, though bruising and local discomfort are common for several days afterward.

Once implanted, the pellet releases hormones through passive diffusion, a process governed by the concentration gradient between the dense pellet core and the surrounding interstitial fluid. The release is not truly "steady" in the pharmacokinetic sense. Studies using serial blood sampling show that pellet implants produce a characteristic curve: hormone levels rise sharply in the first two to four weeks as surface area is high relative to pellet volume, peak somewhere between weeks four and eight, and then gradually decline as the pellet erodes [1]. By month three or four, many patients find their levels have dropped below therapeutic targets, which is the clinical justification for re-implantation every three to six months.

The pellets used in clinical practice are almost universally compounded, meaning they are prepared by compounding pharmacies rather than manufactured to FDA standards. This distinction matters enormously. Compounded products are not subject to the same pre-market testing, potency verification, or sterility requirements that govern FDA-approved hormone therapies [2]. Batch-to-batch variability in compounded pellets has been documented, and because the implant cannot be removed once placed, any dosing error persists for the full duration of the pellet's activity.

The Pharmacokinetics of Hormone Delivery: Why Route Matters

Hormones are not passive cargo. The path they travel from administration site to target tissue shapes their biological effect, their metabolic conversion, and the nature of their risks. The distinction between transdermal delivery and oral delivery, for instance, is not merely academic: oral estrogens pass through the liver on their first pass, where they stimulate the synthesis of clotting factors and sex hormone-binding globulin (SHBG) in ways that transdermal estrogens do not [3]. That single pharmacokinetic difference partly explains why oral estrogens carry a higher venous thromboembolism risk than patches, gels, or creams [4].

Pellets bypass first-pass hepatic metabolism entirely, as do transdermal patches, creams, and subcutaneous injections. This is often cited as an advantage of pellet therapy, but it is equally true of most non-oral alternatives. The relevant pharmacokinetic question, then, is not whether pellets avoid the liver, which they do, but whether their release profile produces hormone levels that are physiologically appropriate and clinically controllable.

The relevant pharmacokinetic question is not whether pellets avoid the liver, but whether their release profile produces hormone levels that are physiologically appropriate and clinically controllable.

In healthy physiology, estradiol and testosterone are released in pulses. Testosterone follows a circadian rhythm with peak levels in the morning and a trough in the evening. Estradiol fluctuates across the menstrual cycle in a pattern that coordinates ovulation, uterine preparation, and feedback signaling to the hypothalamus and pituitary. Pellets produce none of this pulsatility. They deliver a flattened, continuous signal that diverges from the body's own hormonal grammar. Whether this matters clinically remains debated, but it is a meaningful departure from physiological norm.

Patches, by contrast, deliver estradiol transdermally in a relatively steady fashion over 3.5 or 7 days and can be removed immediately if side effects arise. Creams and gels offer daily dosing flexibility. Injections produce a higher peak followed by a gradual trough, which some patients experience as mood or energy fluctuations, though injection intervals can be adjusted to narrow that swing. Each delivery method represents a different tradeoff between convenience, physiological fidelity, and clinical control.

Testosterone Pellets: The Dose Control Problem

Testosterone pellet therapy is particularly common in women being treated for libido, fatigue, and cognitive symptoms, and in men seeking an alternative to injections or topical formulations. The clinical concern that emerges most consistently in the literature is supraphysiological dosing. Supraphysiological means above the upper limit of the normal physiological range, and in women treated with testosterone pellets, it is not a rare edge case.

A 2019 retrospective analysis found that a substantial proportion of women treated with testosterone pellets had total testosterone levels well above the normal female range, in some cases reaching levels more typical of adult males [5]. The consequences of sustained supraphysiological testosterone in women include androgenic side effects such as acne, clitoral enlargement, voice deepening, and male-pattern hair loss. Some of these effects, particularly voice changes and clitoral enlargement, may be permanent even after pellet discontinuation, because the pellet cannot be removed and must simply be allowed to dissolve [2].

The dose determination for pellets is typically based on body weight and symptom questionnaires, a methodology that lacks the precision of iterative dose titration based on blood levels and clinical response. Injections, creams, and gels can all be adjusted incrementally. If a patient on testosterone cream develops acne, the dose can be reduced at the next application. If a patient on pellets develops the same side effect, there is no adjustment available. The clinician and patient can only wait.

If a patient on pellets develops side effects, there is no adjustment available. The clinician and patient can only wait.

This irreversibility is the central clinical objection to pellet therapy, and it stands independent of any question about efficacy. Even if pellets worked as well as other delivery methods in terms of symptom relief, the inability to modify the dose in response to blood levels or adverse effects represents a structural limitation that most endocrinologists consider disqualifying for routine use [2].

Estradiol Pellets and the Question of Breast Cancer Risk

The relationship between estrogen therapy and breast cancer risk has been one of the most scrutinized questions in medicine for the past four decades, and the conclusions are nuanced. The type of estrogen, whether it is combined with a progestogen, the type of progestogen, the route of delivery, the timing relative to menopause, and the duration of use all appear to modulate risk in ways that a simple "estrogen causes breast cancer" or "estrogen prevents breast cancer" framing cannot capture [6].

What makes estradiol pellets particularly relevant to this discussion is the evidence suggesting that supraphysiological estradiol levels, which pellets are prone to producing in the early weeks after implantation, may confer a different risk profile than physiologically dosed transdermal therapy. Estradiol stimulates proliferation in estrogen receptor-positive breast tissue, and higher levels of sustained estradiol exposure are associated in epidemiological data with increased breast cancer risk [7]. Whether the peak-and-trough pattern of pellet delivery is more or less concerning than the steady delivery of a patch has not been definitively established in prospective trials, but the theoretical concern is grounded in established biology.

The Menopause Society (formerly NAMS) and the British Menopause Society both note that subcutaneous pellet implants are not among the recommended standard hormone delivery systems, citing the lack of robust regulatory approval, the compounding quality concerns, and the irreversibility of dosing [8]. These organizations recommend FDA-approved transdermal or oral formulations as the standard of care, with the choice between them guided by individual patient risk factors, preferences, and tolerability.

Procedural Risks of Pellet Implantation

Beyond the pharmacokinetic concerns, pellet therapy involves a minor surgical procedure with its own complication profile. Published case series and retrospective studies report pellet extrusion, where the body pushes the implant toward the surface of the skin, in approximately 3 to 10 percent of insertions [1]. Infection at the insertion site occurs less frequently but can require antibiotic treatment and occasionally surgical drainage. Fibrosis, the formation of scar tissue around the implant site, can complicate re-insertion over time and is more common with repeated procedures.

These procedural risks are not severe by any medical standard, but they exist in contrast to the entirely non-invasive nature of patches, creams, and gels. A patient who develops a skin reaction to an estradiol patch simply removes it and rotates to a different site. A patient who experiences a local reaction to a pellet must manage that reaction while the implant continues to release hormone beneath the skin.

The requirement for an in-office procedure every three to six months also raises questions about cost and access. Pellet insertions are not typically covered by insurance and can cost several hundred dollars per session, adding up to well over a thousand dollars annually. FDA-approved transdermal estradiol patches are available as generics at pharmacies and are frequently covered by insurance, representing a considerably more accessible option for most patients.

How Patches Compare: The Evidence Base

Transdermal estradiol patches have one of the most robust evidence bases of any hormone delivery method. The fundamental mechanism is simple: estradiol dissolved in an adhesive matrix or reservoir system diffuses across the skin into the dermal capillaries, entering systemic circulation without passing through the liver. This produces stable, predictable blood levels that are proportional to patch dose and application area.

The landmark observational data from the E3N cohort study, involving over 80,000 French postmenopausal women followed for more than a decade, found that transdermal estradiol combined with natural progesterone was not associated with increased breast cancer risk at the durations studied, a finding that has been replicated in subsequent analyses [9]. This contrasts with findings for synthetic progestogens combined with oral estrogens, suggesting that both the type of progestogen and the route of estradiol delivery influence breast tissue outcomes.

Transdermal estradiol also has a favorable cardiovascular risk profile compared to oral estrogens. The ESTHER study, a French case-control study, found that transdermal estradiol was not associated with increased venous thromboembolism risk, while oral estrogens roughly doubled it [4]. For women with risk factors for blood clots, including obesity, immobility, or a personal or family history of thromboembolism, transdermal delivery is the clinically preferred route.

Patches do have limitations. Adhesion can be inconsistent, particularly in humid conditions or with physical activity. Skin irritation at the application site affects a minority of users. The seven-day or 3.5-day change interval requires a degree of adherence that some patients find inconvenient. But these are manageable limitations, and the ability to adjust dose by switching to a different patch strength at any point in treatment is a meaningful clinical advantage.

Creams and Gels: Flexibility With a Caveat

Topical estradiol and testosterone creams and gels offer the greatest dosing flexibility of any delivery format. Applied daily to the skin, typically the inner forearm, thigh, or abdomen, they deliver hormone through the same transdermal route as patches but with the ability to fine-tune the dose by adjusting the amount applied. This granularity makes them particularly useful during the initiation of therapy, when the goal is to identify the lowest effective dose, and for managing symptoms through perimenopause, when hormonal requirements fluctuate considerably.

The principal clinical caution with topical preparations is transfer risk. Studies have documented measurable testosterone transfer from a treated adult to a child or partner through skin contact, with documented cases of premature virilization in children living with users of high-potency testosterone gels [10]. This risk is mitigated by covering the application site after application and washing hands thoroughly, but it requires patient education that is sometimes underemphasized in busy clinical settings.

Compounded creams, including Bi-Est 50/50 Cream combining estriol and estradiol, and testosterone topical cream, are widely used in integrative and longevity medicine. They offer personalized formulations that can be adjusted by a prescribing physician and titrated to blood levels over time. The same compounding quality concerns that apply to pellets also apply to compounded creams, so the quality and reliability of the compounding pharmacy matters significantly.

Injections: Precision and Pulsatility

Intramuscular and subcutaneous testosterone injections deliver hormone directly into tissue where it is absorbed into the bloodstream over days. The pharmacokinetic profile of injections is well characterized: levels rise to a peak within 24 to 72 hours of administration, then decline steadily until the next injection. For longer-acting formulations like testosterone cypionate, the standard injection interval is typically one to two weeks, though subcutaneous injections at shorter intervals can produce a smoother, more physiological curve.

The peak-trough variability of injections is the most commonly cited drawback. Some patients notice that energy, libido, and mood track with hormone levels across the injection cycle, feeling well in the days after injection and experiencing a relative dip before the next one. This is a real phenomenon, and it can be addressed by reducing the injection interval, shifting from intramuscular to subcutaneous administration, or switching to a formulation with a longer half-life. The key clinical advantage remains: if levels are too high or too low, the dose and interval can be adjusted at the next administration.

For men, testosterone injections are among the most thoroughly studied hormone therapies available. The Testosterone Trials, a coordinated set of seven clinical trials in older hypogonadal men, used injectable testosterone as the active intervention and provided some of the strongest evidence for the cardiovascular, sexual, physical, and bone density benefits of testosterone optimization in aging men [11]. This evidence base supports injection-based testosterone as a well-characterized intervention, not an experimental one.

Micronized Progesterone: The Progestogen That Behaves Like a Hormone

Any discussion of HRT delivery methods for women must address progesterone, because its absence or presence, and its type, substantially modifies the overall risk-benefit calculation of estrogen therapy. The Women's Health Initiative, the large randomized trial that generated widespread fear of HRT in the early 2000s, used synthetic medroxyprogesterone acetate in combination with conjugated equine estrogens, an oral formulation [12]. Subsequent research established that medroxyprogesterone acetate does not replicate the biological behavior of natural progesterone and carries distinct risks that natural progesterone does not appear to share.

Micronized progesterone, the bioidentical form of the hormone, has a significantly more favorable safety profile with respect to breast tissue, cardiovascular parameters, and sleep. It binds progesterone receptors without the partial glucocorticoid and androgen receptor activity that synthetic progestogens exhibit, which is thought to underlie many of the adverse effects attributed to synthetic forms [9]. When combined with transdermal estradiol, micronized progesterone represents the hormone formulation with the most favorable evidence profile currently available for postmenopausal women.

Pellet therapy, notably, does not typically include progesterone in pellet form because progesterone does not crystallize effectively into pellets. Women who use estradiol pellets and still have a uterus therefore require separate progesterone supplementation to protect the uterine lining, which somewhat undermines the "everything in one implant" appeal of the delivery method.

What the Endocrinology Societies Actually Recommend

The positions of major endocrinology and menopause organizations on pellet therapy are consistent and worth stating clearly. The Endocrine Society, in its clinical practice guidelines on testosterone therapy in women, does not recommend pellet delivery due to concerns about supraphysiological levels and lack of dose adjustability [13]. The Menopause Society similarly excludes pellets from its recommended hormone delivery options, noting the absence of FDA-approved pellet products and the compounding quality concerns [8].

These are not fringe positions. They reflect the consensus judgment of clinicians who have reviewed the available evidence, weighed the risks and benefits against those of established delivery methods, and concluded that pellets do not meet the standard of care for routine hormone optimization. This does not mean that every patient who has used pellets has been harmed, or that no patient has experienced genuine benefit. It means that the structural limitations of the delivery method, primarily the inability to adjust the dose after implantation and the documentation of supraphysiological levels, make it a suboptimal first-line choice when alternatives exist.

The British Menopause Society's position is similarly clear: subcutaneous implants are associated with "tachyphylaxis," a progressive tolerance phenomenon where patients require increasingly large pellets at shorter intervals to achieve the same symptom relief, a pattern that can drive testosterone levels progressively higher over successive cycles [14]. This escalation pattern has no physiological parallel in endogenous hormone production and raises concerns about the long-term endocrine consequences of sustained supraphysiological exposure.

The Business of Pellets and the Information Gap

Part of the reason HRT pellets remain widely available despite the expert consensus against them is economic. Pellet insertion is a procedure with a significant cash-pay revenue stream. Training courses certify practitioners in pellet insertion over a weekend, and the low barrier to entry means that pellet therapy is offered in settings ranging from gynecology practices to medical spas to aesthetics clinics. Patients, understandably seeking relief from real and often debilitating symptoms, are attracted by the simplicity of the pitch: one procedure every few months, no daily medications, no needles at home.

The information asymmetry is significant. Many patients considering pellet therapy are not told that the Endocrine Society does not recommend it for women. They are not shown data on supraphysiological levels. They are not warned that side effects cannot be reversed by removing the implant. These are not obscure caveats found only in specialist literature. They are the central clinical concerns that any prescribing clinician should disclose in the informed consent process.

Many patients considering pellet therapy are not told that the Endocrine Society does not recommend it for women, are not shown data on supraphysiological levels, and are not warned that side effects cannot be reversed by removing the implant.

This is where the telehealth and longevity medicine landscape can serve patients well or poorly, depending on whether it prioritizes patient outcomes or procedure revenue. A clinician-led approach to hormone optimization begins with comprehensive baseline testing, including a Complete Female Hormone Panel or Complete Male Hormone Panel, uses that data to guide the choice of delivery method and dose, and continues to monitor and adjust therapy based on follow-up blood levels and clinical response. That iterative, evidence-based process is incompatible with the fixed-dose, irreversible nature of pellet implantation.

Building a Rational Hormone Optimization Protocol

For women navigating perimenopause and menopause, the current evidence most strongly supports transdermal estradiol combined with micronized progesterone as the foundational hormone regimen, with route and dose individualized to the patient's risk profile, symptoms, and preferences. An estradiol patch offers simplicity and a well-characterized pharmacokinetic profile. Creams and gels offer dosing flexibility. The addition of testosterone for women with persistent low libido, fatigue, or cognitive symptoms is supported by a growing body of evidence, delivered most safely through formulations that allow dose titration, including topical creams or low-dose injectable preparations.

For men with documented hypogonadism, testosterone optimization through TRT injection or TRT cream provides well-established benefits for muscle mass, bone density, sexual function, mood, and metabolic health, with a pharmacokinetic profile that permits ongoing dose adjustment. The starting point for any testosterone protocol is accurate baseline measurement and monitoring through serial blood testing, not a one-size formula based on body weight.

Women's hormonal health requires attention to the full hormonal picture, which is why a Women's Hormone Health program that combines testing, clinical oversight, and adjustable delivery methods provides a meaningfully different standard of care than a pellet insertion performed in a medical spa. The goal is not to maximize hormone levels or to achieve a particular number on a lab report. It is to use the minimum effective dose of the most appropriate formulation to restore hormonal balance and protect long-term healthspan.

Conclusion: Delivery Method Is Not a Minor Detail

The question of HRT pellets versus patches, creams, and injections is ultimately a question about what responsible hormone medicine looks like. Hormones are among the most potent signaling molecules in the body. Small changes in their concentration, timing, and pattern of exposure have downstream effects on cardiovascular tissue, breast tissue, bone, brain, and metabolic function that play out over years and decades. A delivery method that cannot be adjusted, that routinely produces supraphysiological levels, and that has not earned the endorsement of the major professional bodies governing endocrinology and menopause medicine is not a minor variation on standard therapy. It is a structural departure from it.

The patients who turn to pellet therapy are, almost universally, people with genuine and significant symptoms: the hot flashes that disrupt sleep for months on end, the loss of libido that strains relationships, the fatigue and cognitive fog that erode professional and personal life during perimenopause or hypogonadism. These symptoms deserve effective treatment. The evidence supports that effective treatment is available, through delivery methods that preserve the ability to adjust, monitor, and protect. The choice of how to deliver a hormone is not a preference to be left to marketing. It is a clinical decision with real consequences for the people making it.